Abstracts Archive - Page 808 of 2607 - ACR Meeting Abstracts

Abstract Number: 1543 • ACR Convergence 2021
Epidemiology and Disease Burden of Hospitalized Children with Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 Infection in Canada: A Canadian Pediatric Surveillance Program National Prospective Study
Tala El Tal¹, Marie-Paule Morin², Shaun Morris³, Roberta Berard⁴, Daniel Farrar⁵, Fatima Kakkar⁶, Charlotte Moore-Hepburn⁷, Elie Haddad², Rosie Scuccimarri⁸ and Rae Yeung⁹, ¹University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ²CHU Sainte-Justine, Montréal, QC, Canada, ³Centre for Global Child Health, The Hospital for Sick Children, Division of Infectious Diseases, The Hospital for Sick Children, Toronto; Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Toronto, ON, Canada, ⁴London Health Sciences Centre, London, ON, Canada, ⁵Centre for Global Child Health, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Division of Infectious Diseases, CHU Sainte-Justine, Montréal, QC, Canada, ⁷Division of Paediatric Medicine, Hospital for Sick Children, Toronto, ON, Canada, ⁸McGill University/Montreal Children's Hospital, Montréal, QC, Canada, ⁹The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: As of May 2021, Canada had reached over 1.3 million confirmed cases of SARS-CoV-2 infection, and over 25,000 deaths. This study identified children in…
Abstract Number: 1544 • ACR Convergence 2021
Clinical Course and Risk Factors for Severe/Critical COVID-19 in Patients with Rheumatic Diseases – a Multicenter, Nationwide Study
Sofia Carvalho Barreira¹, Ana Rita Cruz-Machado¹, Matilde Bandeira¹, Catarina Duarte², Maria Rato³, Bruno Fernandes⁴, Salomé Garcia³, Filipe Pinheiro³, Miguel Bernardes³, Nathalie Madeira⁵, Cláudia Miguel⁵, Rita Torres⁶, Ana Bento Silva⁶, Jorge Pestana⁷, Diogo Almeida⁸, Carolina Mazeda⁹, Filipe Cunha Santos¹⁰, Patrícia Pinto¹¹, Marlene Sousa¹², Hugo Parente¹³, Graca Sequeira¹⁴, Maria José Santos⁷, João Eurico Fonseca¹⁵ and Vasco C Romão¹⁵, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ²Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ³Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, ⁵Rheumatology Department, Instituto Português de Reumatologia, Lisbon, Portugal, ⁶Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ⁷Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ⁸Rheumatology Department, Hospital de Braga, Braga, ⁹Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ¹⁰Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, ¹¹Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Gaia, Portugal, ¹²Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹³Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal., Ponte de Lima, Portugal, ¹⁴Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ¹⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
Background/Purpose: Since the beginning of the COVID-19 pandemic, some studies have addressed risk factors for severe forms of the disease in patients with rheumatic diseases.…
Abstract Number: 1545 • ACR Convergence 2021
Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor
Wonho Choi¹, Soo Min Ahn², Yong Gil Kim¹, Chang-Keun Lee¹, Bin Yoo² and Seokchan Hong¹, ¹Asan Medical Center, Seoul, Republic of Korea, ²ASAN MEDICAL CENTER, Seoul, South Korea
Background/Purpose: Janus kinase inhibitor (JAKi) increases the risk of the reactivation of herpes zoster (HZ) virus and may thus be temporarily discontinued in cases of…
Abstract Number: 1546 • ACR Convergence 2021
Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients
Ingrid Jyssum¹, Anne Therese Tveter¹, Fridtjof Lund-Johansen², Ludvig Munthe², Sella Provan¹, Kristin Jørgensen³, Gunnveig Grødeland², Grete Kro², David Warren², Joseph Sexton¹, Tore Kvien¹, Siri Mjaaland⁴, Espen Haavardsholm¹, John Torgils Vaage², Silje Watterdal Syversen¹ and Guro Goll¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Oslo University Hospital, Oslo, Norway, ³Akershus University Hospital, Lørenskog, Norway, ⁴Norwegian Institute of Public Health, Oslo, Norway
Background/Purpose: To assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive medication for inflammatory arthritis.Methods: Adult patients…
Abstract Number: 1547 • ACR Convergence 2021
Potential Predictors of Outcome for Anakinra Treatment in COVID-19 Patients with Macrophage Activation Syndrome
Shirkhan Amikishiyev¹, Rabia Deniz², Mehmet Guven Gunver³, Sarvan Aghamuradov¹, Nevzat Koca¹, Burak Ince¹, Murat Bektas¹, Gorkem Durak⁴, Murat Kose², Mustafa Erelel⁵, Arif Atahan Çağatay⁶, Sevgi Kalayoglu Besısık⁷, Figen Esen⁵ and Ahmet Gül⁸, ¹Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ²Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ³Department of Biostatistics, Istanbul Medical Faculty, İstanbul, Turkey,, Istanbul, Turkey, ⁴Istanbul Faculty of Medicine, Istanbul University, Department of Radiology, İstanbul, Turkey, ⁵Istanbul Faculty of Medicine, Istanbul University, Department of Anesthesiology, İstanbul, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Department of Infectious Diseases and Clinical Microbiology, İstanbul, Turkey, ⁷Istanbul Faculty of Medicine, Istanbul University, Division of Hematology and Therapeutic Apheresis Unit, İstanbul, Turkey, ⁸Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
Background/Purpose: Coronavirus Disease 2019 (COVID-19) runs a severe course in a subset of patients with acute respiratory distress syndrome and multiorgan failure, and a hyperinflammatory…
Abstract Number: 1548 • ACR Convergence 2021
Q Fever as a Mimicker of Rheumatologic Conditions: A Case Series from Two Tertiary Care Academic Centers in Southern California
Manushi Aggarwal and Marven Cabling, Loma Linda University Health, Redlands, CA
Background/Purpose: Q fever, an endemic disease in Southern California, is a zoonosis caused by Coxiella burnetii. The infection can present with multiple non-specific acute and chronic manifestations including fever, headache,…
Abstract Number: 1549 • ACR Convergence 2021
Experience from a Diverse Rheumatology Cohort with COVID-19: Are We Doing Better Than We Expected?
Michael Grant¹, Matas Orentas², Sobia Hassan¹, Sonali Khandelwal¹, Donyea Moore³ and Najia Shakoor¹, ¹Rush University, Chicago, IL, ²RUMC, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: The COVID-19 pandemic has been particularly concerning for patients with rheumatologic conditions because they are potentially predisposed to more severe outcomes. Studies have suggested…
Abstract Number: 1550 • ACR Convergence 2021
Flares and Side Effects After COVID-19 Vaccination in Patients with Rheumatic Diseases
Anna Carbone, Gentiana Vukatana, Enrica Vandelli, Marica Trevisani, Elisa Rossi, Rita Mulè and Marco Fusconi, Rheumatology Unit, Azienda Ospedaliero-Universitaria Bologna, Bologna, Italy
Background/Purpose: There is increasing interest in the safety of COVID-19 vaccination in patients with underlying chronic conditions. We investigated the rates of side effects and/or…
Abstract Number: 1551 • ACR Convergence 2021
Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination
Tal Gazitt¹, Joy Feld², Amir Haddad³, Muna Elias⁴, Nizar Hijazi⁴, Nili Stein⁴, Victoria Furer⁵, Tali Eviatar⁶, Hagit Peleg⁷, Ori Elkayam⁸ and Devy Zisman⁴, ¹Carmel Hospital, Haifa, Israel, ²Carmel and Zvulun Medical Centre, Haifa, Israel, ³Carmel Medical Centre, Haifa, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel Aviv Sourasky Medical Center, Givataim, Israel, ⁷Hadassah Medical Center, Jerusalem, Israel, ⁸Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: The rapid spread of the COVID-19 pandemic has created the need for mass vaccination of patients with autoimmune rheumatic disease (AIIRD) despite the lack…
Abstract Number: 1552 • ACR Convergence 2021
Systemic Autoimmune Conditions and Hospital Admissions in Covid-19 Infection
Inés Perez - Sancristobal¹, Leticia Lopez Pedraza², María Paula Álvarez Hernández¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez⁴, Cristina Martínez - Prada⁴, Luis Rodriguez Rodriguez⁵, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁶, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Spain, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ⁵Hospital Clinico San Carlos, Madrid, Spain, ⁶Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: The COVID-19 pandemic continues worldwide and has had a strong impact on public health. From the beginning of the pandemic, efforts were intensified to…
Abstract Number: 1553 • ACR Convergence 2021
Low-dose Tocilizumab in the Treatment of COVID-19 Pneumonitis: 90-day Mortality Follow-up
Lauren He¹, Garth Strohbehn² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²VA Ann Arbor Center for Clinical Management and Research, Chicago, IL, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: Tocilizumab (TCZ) for treatment of severe coronavirus disease 2019 (COVID-19) pneumonia decreases the probability of progression to invasive mechanical ventilation (CORIMUNO-TOCI) or death (REMAP-CAP,…
Abstract Number: 1554 • ACR Convergence 2021
COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases
Valeria Valerio¹, Emmanouil Rampakakis², Marie Hudson³, Sasha Bernatsky³, Elizabeth M. Hazel³ and Ines Colmegna⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²JSS Medical Research, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Vaccination is fundamental to reduce COVID-19 risk and its complications. Vaccine hesitancy is a threat to COVID-19 vaccination uptake. We assessed the frequency of…
Abstract Number: 1555 • ACR Convergence 2021
Clinical Outcomes of Coronavirus Disease-2019 (COVID-19) in Hospitalized Patients with Rheumatic and Musculoskeletal Diseases (RMD)
Ikwinder Kaur¹, Mohsin Mughal², Abdul Asbeutah³, Mili Kakadia², Reem Alhashemi⁴, Hasan Mirza⁵, Harjot Jagdey⁶, Rasha Alhashimi⁷, vishakha sirpal², Punit Jariwala² and Eugenio Capitle⁸, ¹Monmouth Medical Center, an affiliate of Rutgers health system, Long Branch, NJ, ²Monmouth Medical Center, Long Branch, NJ, ³University of Tennessee Health Science Center, Memphis, TN, ⁴Monmouth Medical Center, Long Branch, NJ, ⁵Berkshire Medical Center, Pittsfield, MA, ⁶BronxCare Hospital, Bronx, NY, ⁷BIDMC, Havard, Boston, MA, ⁸Rutgers New Jersey Medical School, New Brunswick, NJ
Background/Purpose: COVID-19 has been implicated in an exaggerated inflammatory response by activating both innate and adaptive immune responses. Rheumatic disease patients are a vulnerable population…
Abstract Number: 1556 • ACR Convergence 2021
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
Ines Perez - Sancristobal¹, Dalifer Freites¹, Leticia Lopez Pedraza², Maria Paula Alvarez Hernandez¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez¹, Cristina Vadillo¹, Luis Rodriguez Rodriguez⁴, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁵, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clinico San Carlos, Madrid, Spain, ⁵Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…
Abstract Number: 1557 • ACR Convergence 2021
Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
Ana Medeiros-Ribeiro¹, Nadia Aikawa¹, Carla Gonçalves Schahin Saad¹, Emily Figueiredo Vieira Neves Yuki¹, Tatiana do Nascimento Pedrosa¹, Solange Fusco¹, Priscila Rojo¹, Rosa Pereira¹, Samuel Shinjo¹, Danieli Andrade¹, Percival Sampaio-Barros¹, Carolina Ribeiro¹, Giordano Deveza¹, Victor Adriano de Oliveira Martins¹, Clovis Artur Silva¹, Marta Lopes¹, Alberto Duarte¹, Leila Antonangelo¹, Ester Sabino¹, Esper Kallas¹, Sandra Gofinet Pasoto² and Eloisa Bonfá¹, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Hospital das Clinicas de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Brazil is among the countries with the highest numbers of confirmed cases and deaths by COVID-19. CoronaVac (SARS-CoV-2 inactivated vaccine) has been largely used…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].